SG99594G - Angiostatic steroids - Google Patents

Angiostatic steroids

Info

Publication number
SG99594G
SG99594G SG99594A SG99594A SG99594G SG 99594 G SG99594 G SG 99594G SG 99594 A SG99594 A SG 99594A SG 99594 A SG99594 A SG 99594A SG 99594 G SG99594 G SG 99594G
Authority
SG
Singapore
Prior art keywords
bond
alkyl
beta
integer
forms
Prior art date
Application number
SG99594A
Other languages
English (en)
Inventor
Paul A Aristoff
Harvey L Skulnick
Wendell Wierenga
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to SG99594A priority Critical patent/SG99594G/en
Publication of SG99594G publication Critical patent/SG99594G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG99594A 1985-10-23 1994-07-21 Angiostatic steroids SG99594G (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG99594A SG99594G (en) 1985-10-23 1994-07-21 Angiostatic steroids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79056485A 1985-10-23 1985-10-23
US81186685A 1985-12-20 1985-12-20
SG99594A SG99594G (en) 1985-10-23 1994-07-21 Angiostatic steroids

Publications (1)

Publication Number Publication Date
SG99594G true SG99594G (en) 1994-10-28

Family

ID=27121047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG99594A SG99594G (en) 1985-10-23 1994-07-21 Angiostatic steroids

Country Status (9)

Country Link
EP (2) EP0221705A1 (el)
JP (1) JP2545522B2 (el)
AT (1) ATE66002T1 (el)
DE (1) DE3680788D1 (el)
ES (1) ES2041245T3 (el)
GR (1) GR3002675T3 (el)
HK (1) HK129594A (el)
SG (1) SG99594G (el)
WO (1) WO1987002672A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
CA2081205C (en) * 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
DK0614463T3 (da) * 1991-11-22 2003-03-31 Alcon Lab Inc Angiostatiske steroider
US5929111A (en) * 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
BR122020006408B1 (pt) 2013-03-29 2021-09-28 The Johns Hopkins University Dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica e uso de c. novyi nt para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
CA3168216A1 (en) 2015-01-30 2016-08-04 Biomed Valley Discoveries, Inc. Crystalline c21h22cl2n4o2 malonate
EP3250562A4 (en) 2015-01-30 2018-07-11 Biomed Valley Discoveries, Inc. Crystalline forms of c21h22ci2n4o2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868783A (en) * 1958-04-14 1959-01-13 Upjohn Co 11-oxygenated-17alpha, 21-dihydroxy-4-pregnen-20-ones and the 21-esters thereof
US3098085A (en) * 1958-07-04 1963-07-16 Ciba Geigy Corp Process for the manufacture of 16alpha-methyl-allopregnanes substituted in the 21-position
US3083199A (en) * 1961-01-11 1963-03-26 Farmaceutici Italia delta3-5alpha-steroids and 3alpha-hydroxy-5alpha-steroids and the preparation thereof
US3045033A (en) * 1961-05-10 1962-07-17 Schering Corp Water soluble cyclophosphate esters of steroids and process for preparing same
US3402173A (en) 1965-03-19 1968-09-17 Syntex Corp 18-lower alkyl pregnanes and derivatives
US3780177A (en) 1967-06-16 1973-12-18 Warner Lambert Co 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
DE2257132C3 (de) * 1972-11-18 1982-05-13 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Reduktion von 3-Ketosteroiden
US3980778A (en) 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
EP0001737B1 (de) * 1977-10-26 1981-01-07 Schering Aktiengesellschaft 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
US4318853A (en) * 1980-01-31 1982-03-09 The Upjohn Company 9β,11β-Epoxy-5β-corticoids
ZA817929B (en) 1980-12-22 1982-10-27 Upjohn Co 5alpha-and 5beta-androstane-17beta-carboxylates
US4456602A (en) * 1982-08-23 1984-06-26 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4469689A (en) * 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
CA1310009C (en) * 1984-03-28 1992-11-10 John Mark Braughler Ester prodrugs of steroids
US4588718A (en) * 1984-03-28 1986-05-13 The Upjohn Company Carboxy containing ester prodrugs of corticosteroids

Also Published As

Publication number Publication date
EP0221705A1 (en) 1987-05-13
JPS63501292A (ja) 1988-05-19
ES2041245T3 (es) 1993-11-16
DE3680788D1 (de) 1991-09-12
ATE66002T1 (de) 1991-08-15
GR3002675T3 (en) 1993-01-25
EP0245357B1 (en) 1991-08-07
EP0245357A1 (en) 1987-11-19
HK129594A (en) 1994-11-25
WO1987002672A1 (en) 1987-05-07
JP2545522B2 (ja) 1996-10-23

Similar Documents

Publication Publication Date Title
GR3002675T3 (en) Angiostatic steroids
ES8401498A1 (es) Procedimiento de preparacion de nuevos derivados esteroides sustituidos en 11b.
KR900005984A (ko) 눈의 고혈압 조절용 조성물 및 그 조절방법
IT1213029B (it) Chelati di ioni metallici paramagnetici.
ES467434A1 (es) Procedimiento para la obtencion de esteres de acidos andros-tadien-17-carboxilicos.
UA42674C2 (uk) Спосіб одержання похідних 3-кето-4-азастероїду та проміжні сполуки для його здійснення
GB1488903A (en) X-ray contrast media
US3743686A (en) Unsaturated polyester resins which cure in the presence of water and which contain at least one dehydro monomer
DE69203551D1 (de) Biologisch abbaubarer Copolyester von 4-Hydroxyprolin und diesen enthaltende pharmazeutische Zusammensetzung.
GB1393616A (en) Preparation of piperidine-spiro-hydantoin derivatives
ES8405420A1 (es) Nuevo proceso para la preparacion de esteres de esteroides.
ES433816A1 (es) Procedimiento para preparar derivados de amidoxina.
IL100465A (en) 6, 7-MODIFIED 11b-ARYL- 4-OESTRENE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
GB1466028A (en) Phosphonic acid esters containing a heterocyclic ring and having flame retardant properties
ES456416A1 (es) Procedimiento para la obtencion de derivados de 14-dioxi- vincanol.
WO2002048250A2 (en) Organic thiol metal-free stabilizers and plasticizers for halogen-containing polymers
ES382485A1 (es) Un procedimiento para la preparacion de acidos alquenoicos sustituidos.
ES8407084A1 (es) Procedimiento para preparar composiciones resinosas ignifugas de polifenileneter-estireno.
GB1421075A (en) Bis basic esters of tricyclic ompounds
US3539529A (en) Polyvinylchloride stabilized compositions
ES8102579A1 (es) Un procedimiento para la preparacion de un nuevo esteroide 21-alquilado.
GB1479424A (en) Flame resistant polyamide compositions
US2933465A (en) Vinyl chloride resins stabilized with titanium chelates
ES368120A1 (es) Procedimiento para la preparacion de derivados de 14 alfa, 17 alfa, 17 alfa-metilendioxipregnano.
JPS56120699A (en) 177aminoo166hydroxysteroid of novel androstane and estrane* its derivative and its drug composition